Last reviewed · How we verify
Naropeine
Naropeine is a Small molecule drug developed by University Hospital, Rouen. It is currently in Phase 3 development for Anesthesia for cesarean section, Local anesthesia, Major Nerve Block for Surgery.
Naropeine is being studied in clinical trials for various conditions, including post-mastectomy neuropathic pain syndrome, diaphragmatic paralysis, breast cancer, hysterotomy, and ENT cancers. The interventions being tested include a capsaicin 8% patch, serratus plane block, and botulinum toxin A.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Naropeine |
|---|---|
| Sponsor | University Hospital, Rouen |
| Target | Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 3 |
Approved indications
- Anesthesia for cesarean section
- Local anesthesia
- Major Nerve Block for Surgery
- Regional Anesthesia for Labor Pain
- Regional Anesthesia for Postoperative Pain
- Regional Anesthesia for Surgery
Common side effects
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site (PHASE3)
- Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain (PHASE3)
- Effects of Insufflated Gas on Core Temperature and Post-operative Pain During Laparoscopic Surgery (NA)
- MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery (PHASE3)
- Evaluation of the Superficial Cervical Plexus Block in Oncological Throat and Neck Surgery (NA)
- Deep Posterior Post Gluteal Compartment Block in Total Hip Arthroplasty: Feasability and Safety (NA)
- Chest Wall Block After Sternotomy: Randomized Controlled Trial in Cardiac Surgery: (PABLOS Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naropeine CI brief — competitive landscape report
- Naropeine updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI
Frequently asked questions about Naropeine
What is Naropeine?
What is Naropeine used for?
Who makes Naropeine?
What development phase is Naropeine in?
What does Naropeine target?
Related
- Target: All drugs targeting Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
- Manufacturer: University Hospital, Rouen — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Anesthesia for cesarean section
- Indication: Drugs for Local anesthesia
- Indication: Drugs for Major Nerve Block for Surgery
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing